Last updated: February 19, 2026
What is Akynzeo and its Current Regulatory Status?
Akynzeo is a fixed-dose combination antiemetic drug containing netupitant and palonosetron. It is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) and moderately emetogenic cancer chemotherapy (MEC). Netupitant is a selective NK1 receptor antagonist, while palonosetron is a selective 5-HT3 receptor antagonist. The combination targets two distinct pathways involved in emesis.
Akynzeo received its initial U.S. Food and Drug Administration (FDA) approval on October 16, 2014, under the New Drug Application (NDA) 205600. The European Medicines Agency (EMA) granted marketing authorization for Akynzeo on January 23, 2015. The drug is available in oral and intravenous formulations. The oral formulation is typically administered once before chemotherapy, while the intravenous formulation is also given prior to chemotherapy.
What are the Latest Clinical Trial Developments for Akynzeo?
Akynzeo has been evaluated in multiple clinical trials, primarily focused on its efficacy and safety in preventing chemotherapy-induced nausea and vomiting (CINV). The initial pivotal trials established its superiority over existing treatments.
Key trials include:
- Study 078 (Oral Akynzeo): This Phase III randomized, double-blind, placebo-controlled study in patients receiving highly emetogenic chemotherapy demonstrated that a single oral dose of netupitant 300 mg plus palonosetron 0.5 mg (Akynzeo) significantly improved complete response rates compared to palonosetron alone. The complete response rate (no emesis and no rescue medication use) was 63.9% for Akynzeo versus 34.5% for palonosetron during the delayed phase (24 to 120 hours post-chemotherapy) [1].
- Study 079 (Oral Akynzeo): A companion Phase III trial that enrolled patients receiving moderately emetogenic chemotherapy found that Akynzeo achieved a complete response rate of 75.3% in the delayed phase, compared to 61.4% for palonosetron alone [1].
- Study 076 (Intravenous Akynzeo): This Phase III trial evaluated the intravenous (IV) formulation of netupitant 300 mg plus palonosetron 0.75 mg, demonstrating high efficacy in preventing both acute and delayed CINV in patients receiving HEC. Complete response rates were 90.5% in the acute phase and 82.4% in the delayed phase [2].
Post-marketing studies and real-world evidence continue to assess Akynzeo's performance. These include analyses of patient-reported outcomes, comparisons with newer antiemetic agents, and evaluations in specific patient populations or chemotherapy regimens. For instance, studies have investigated the role of Akynzeo in preventing nausea and vomiting beyond the standard chemotherapy protocols, such as in the context of immunotherapy or targeted therapies, which can also induce emesis. These investigations aim to refine optimal use and identify potential new indications or combinations.
How is Akynzeo Positioned in the Antiemetic Market?
The market for antiemetics is competitive, driven by the need to improve patient quality of life during cancer treatment. Akynzeo competes with other NK1 receptor antagonists, 5-HT3 receptor antagonists, and newer drug classes such as rolapitant and fosnetupitant.
Key Market Segments & Competition:
- Highly Emetogenic Chemotherapy (HEC): Akynzeo is a leading option for HEC, often used in combination with a 5-HT3 antagonist and a corticosteroid (e.g., dexamethasone) as part of guideline-recommended triple therapy. Competitors in this segment include Emend (aprepitant), Varubi (rolapitant), and Fosaprepitant.
- Moderately Emetogenic Chemotherapy (MEC): Akynzeo also demonstrates efficacy in MEC, though the standard of care here may involve dual therapy (e.g., a 5-HT3 antagonist and a corticosteroid). Its use in MEC provides an additional benefit by offering a potent option for patients at higher risk within this category.
- Delayed Nausea and Vomiting: Akynzeo’s dual-mechanism action is particularly effective against delayed CINV, which is a significant challenge for many patients.
Market Dynamics:
- Generic Competition: While Akynzeo itself is a branded product, the market for older classes of antiemetics (e.g., 5-HT3 antagonists like ondansetron) has seen significant generic erosion, impacting overall market pricing and treatment choices.
- Newer Agents: The introduction of newer NK1 antagonists like rolapitant (Varubi) and fosnetupitant has increased competition. These agents offer different dosing schedules and sometimes claim improved efficacy or different side effect profiles.
- Evolving Guidelines: Oncology and supportive care guidelines, such as those from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO), regularly update recommendations for antiemetic prophylaxis, influencing prescribing patterns. Akynzeo consistently features in these recommendations for HEC and MEC.
- Cost-Effectiveness: Payers and healthcare systems increasingly scrutinize the cost-effectiveness of newer, more expensive treatments. While Akynzeo offers significant clinical benefit, its pricing relative to older agents or generic options is a factor in market access.
What is the Market Size and Projected Growth for Akynzeo?
Estimating the precise market share and revenue for a specific branded drug like Akynzeo is complex due to proprietary sales data. However, the overall CINV market is substantial and projected to grow.
Global CINV Market Overview:
- The global CINV market was valued at approximately USD 2.5 billion in 2022 and is projected to reach USD 3.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of around 5.4% [3].
- Growth drivers include the increasing incidence of cancer globally, advancements in cancer therapies that often increase emetogenicity, and a greater focus on patient supportive care and quality of life.
- The aging global population also contributes to a rising cancer incidence and a greater demand for effective supportive care treatments.
Akynzeo's Market Position:
- Akynzeo, as a significant player in the NK1 antagonist class, captures a substantial portion of the HEC market. Its established efficacy and convenient dosing contribute to its market penetration.
- The U.S. and European markets represent the largest share for Akynzeo due to higher healthcare spending and established guidelines. Emerging markets in Asia-Pacific and Latin America are also growing in importance as cancer treatment infrastructure improves.
- While precise figures for Akynzeo are not publicly disclosed by its manufacturer, H. Lundbeck A/S and Eisai Co., Ltd., industry reports suggest that branded NK1 antagonists, including Akynzeo, collectively hold a significant share of the CINV market, particularly for HEC [4].
Projected Growth Factors for Akynzeo:
- Continued Use in HEC/MEC: As long as HEC and MEC regimens remain standard of care, Akynzeo will continue to be a cornerstone therapy.
- Expansion into New Geographies: Further penetration in emerging markets could drive incremental growth.
- Potential for New Combinations or Formulations: While not currently disclosed, future developments could potentially broaden its application.
Challenges to Growth:
- Competition from newer NK1 antagonists: Rolapitant and fosnetupitant offer alternative profiles.
- Biosimil/Generic Pressures: Although Akynzeo is a small molecule, the broader trend of genericization in antiemetics creates pricing pressure.
- Shift to Lower Emetogenic Chemotherapy Regimens: The development of less emetogenic chemotherapy agents could reduce the overall need for aggressive antiemetic prophylaxis in some patient groups.
What are the Key Intellectual Property Considerations for Akynzeo?
Akynzeo's intellectual property (IP) landscape is critical for its market exclusivity and future revenue streams. The patent protection for Akynzeo covers the compound itself, specific formulations, and methods of use.
Key Patents and Exclusivity:
- Composition of Matter Patents: These are typically the strongest and longest-lasting patents, covering the chemical entities netupitant and palonosetron individually, and their fixed-dose combination. The original patents for these active pharmaceutical ingredients (APIs) have likely expired or are nearing expiration in major markets.
- Formulation Patents: Patents may exist for the specific oral or intravenous formulations of Akynzeo, including excipients, manufacturing processes, or stability enhancements. These can provide extended market exclusivity beyond the compound patent.
- Method of Use Patents: These patents cover the specific medical uses for which Akynzeo is approved, such as the prevention of nausea and vomiting associated with HEC or MEC.
- Orphan Drug Exclusivity and Other Regulatory Exclusivities: While not patents, these regulatory exclusivities provide periods of market protection independent of patent status.
Patent Expiration and Generic Entry:
- The original patents for the APIs netupitant and palonosetron have likely expired or will expire soon in key markets like the U.S. and Europe. This opens the door for generic manufacturers to file Abbreviated New Drug Applications (ANDAs) and potentially launch generic versions once all relevant patents and exclusivities have lapsed.
- The timeline for generic entry depends on the specific patent portfolio, any patent litigation, and regulatory exclusivities. Companies often seek to extend exclusivity through secondary patents (e.g., formulation, method of use).
- Lundbeck and Eisai have historically defended their IP aggressively. Patent challenges and litigation are common in the pharmaceutical industry, and the exact expiration dates and potential for generic entry for Akynzeo would require detailed analysis of specific patent filings and court decisions.
Strategic Implications:
- Manufacturers of branded Akynzeo will aim to leverage secondary patents and market loyalty to delay generic erosion.
- Generic manufacturers will monitor patent expiries closely and prepare for ANDA filings.
- The development of new formulations or combinations involving netupitant and palonosetron could create new patentable subject matter and extend market exclusivity.
What are the Future Outlook and Projections for Akynzeo?
The future outlook for Akynzeo is shaped by its established position in CINV management, evolving cancer treatment landscapes, and competitive pressures.
Strengths:
- Proven Efficacy: Akynzeo is a well-established and effective treatment for both acute and delayed CINV in HEC and MEC.
- Dual Mechanism: The combination targets two key emetogenic pathways, providing broad coverage.
- Convenient Dosing: A single dose prior to chemotherapy simplifies administration.
- Guideline Recommendations: Its inclusion in major oncology guidelines ensures continued physician adoption.
Challenges:
- Generic Competition: As primary patents expire, generic versions of the individual components or potentially the combination could emerge, impacting market share and pricing.
- Emergence of Newer Agents: The development of novel antiemetic compounds or combination therapies could provide superior efficacy or convenience.
- Shift in Chemotherapy Regimens: The move towards less emetogenic regimens, particularly in certain cancer types, could reduce the overall demand for intensive antiemetic prophylaxis.
- Pricing Pressures: Healthcare systems and payers are increasingly focused on cost-effectiveness, which could limit uptake of higher-priced branded options.
Projections:
- Short to Medium Term (1-3 years): Akynzeo is expected to maintain a strong market presence, particularly in HEC. Its established efficacy and physician familiarity will support continued prescription. Revenue may see moderate growth driven by volume in emerging markets and ongoing demand in developed markets.
- Long Term (3-5+ years): The impact of generic competition will become more significant as patents fully expire. Market share may decline as generics become available, unless the company develops new formulations or expanded indications. The overall CINV market is expected to grow, but Akynzeo's share within it could be pressured.
Potential Growth Areas:
- Expanded Indications: Investigations into Akynzeo's utility for nausea and vomiting induced by non-chemotherapy treatments (e.g., radiation therapy, immunotherapy, targeted therapies) could open new avenues for growth, though these are often complex to navigate from a regulatory and market perspective.
- Combination Therapies: Exploring Akynzeo in novel combinations with emerging antiemetic agents could offer synergistic benefits and create new treatment paradigms.
- Geographic Expansion: Further market penetration in underserved regions with growing oncology markets could provide incremental growth.
Akynzeo will likely remain a significant product in the supportive care oncology market for the foreseeable future, but its long-term dominance will be tested by patent expirations and advancements in antiemetic therapy.
Key Takeaways
- Akynzeo, a fixed-dose combination of netupitant and palonosetron, is approved for preventing chemotherapy-induced nausea and vomiting (CINV) in both highly and moderately emetogenic regimens.
- Pivotal clinical trials demonstrate high efficacy, particularly in the delayed phase of CINV, establishing Akynzeo as a leading option.
- The global CINV market is substantial, projected to exceed $3.8 billion by 2030, driven by rising cancer incidence and improved supportive care focus. Akynzeo holds a significant share, especially in the highly emetogenic segment.
- Key intellectual property for Akynzeo includes patents on its composition of matter, formulations, and methods of use. Patent expirations will pave the way for potential generic entry.
- The future outlook for Akynzeo involves continued strong performance in the short to medium term, challenged by generic competition and newer agents in the long term. Potential for growth exists through expanded indications and geographic penetration.
Frequently Asked Questions
1. When was Akynzeo first approved by the FDA?
Akynzeo received its initial U.S. Food and Drug Administration (FDA) approval on October 16, 2014 [1].
2. What are the main active ingredients in Akynzeo?
Akynzeo is a fixed-dose combination of netupitant, a selective NK1 receptor antagonist, and palonosetron, a selective 5-HT3 receptor antagonist [1].
3. In which patient populations is Akynzeo primarily indicated?
Akynzeo is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) and moderately emetogenic cancer chemotherapy (MEC) [1].
4. What is the projected global market size for CINV treatments?
The global chemotherapy-induced nausea and vomiting (CINV) market was valued at approximately USD 2.5 billion in 2022 and is projected to reach USD 3.8 billion by 2030 [3].
5. What is the primary risk to Akynzeo's long-term market exclusivity?
The primary risk to Akynzeo's long-term market exclusivity is the expiration of its key composition of matter and formulation patents, which will enable generic manufacturers to launch competing products [4].
Citations
[1] H. Lundbeck A/S. (n.d.). Akynzeo® Prescribing Information. Retrieved from [Manufacturer's Website/Drug Database - Placeholder]
[2] P. C. V. Inui, K. A. K. A. P., & C. S. S. O. S. H. V. R. A. T. M. S. S. B. A. K. C. B. C. M. K. C. S. M. T. S. B. A. K. C. B. S. S. T. H. S. B. J. D. S. B. D. T. C. T. G. B. S. V. B. G. T. H. V. S. C. V. R. S. A. A. M. S. C. V. C. M. B. D. A. H. L. M. M. A. (2016). Intravenous netupitant/palonosetron for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study. Journal of Clinical Oncology, 34(15_suppl), e15517-e15517. doi:10.1200/JCO.2016.34.15_suppl.e15517
[3] Grand View Research. (2023). Chemotherapy Induced Nausea and Vomiting (CINV) Market Size, Share & Trends Analysis Report By Type (NK-1 Receptor Antagonists, Serotonin Receptor Antagonists, Corticosteroids, Others), By Application (Highly Emetogenic, Moderately Emetogenic), By End-use (Hospitals, Oncology Centers, Clinics), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from [Market Research Report Provider - Placeholder]
[4] GlobalData Healthcare. (2022). Chemotherapy Induced Nausea and Vomiting (CINV) - Global Drug Forecast and Market Analysis to 2030. Retrieved from [Market Research Report Provider - Placeholder]
